Nasdaq GlobeNewswire

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018

Del

LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018.

At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including:

- Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; 
- Allocation of the financial year's results;
- Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; 
- Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017;
- Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma Group.

The full results of all matters voted on at the meeting can be viewed on the Company's website at www.erytech.com, under the Shareholders Meeting tab within the Investors section.

About ERYTECH:  www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH's initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.

The Company's lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.

Eryaspase demonstrated promising efficacy and safety results in various clinical trials in ALL, as well as in a Phase 2b trial in second-line pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.

ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). A large-scale manufacturing facility is under construction in New Jersey (USA).

In addition to eryaspase, ERYTECH is developing erymethionase, methionine-y-lyase encapsulated in red blood cells, to target cancer cells' amino acid metabolism and induce tumor cell starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS 

ERYTECH    
Naomi Eichenbaum
Director Investor Relations
  NewCap
Julien Perez
Investor relations
Nicolas Merigeau
Media relations
     
     
+33 4 78 74 44 38
+1 917 312 5151
naomi.eichenbaum@erytech.com  
  +33 1 44 71 98 52 
ERYTECH@newcap.eu  



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Erytech Pharma S.A. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Elite Capital & Gas broadens financial services and signs a deal with Tabarak Investment Capital Limited17.10.2018 16:30Pressemelding

DUBAI, United Arab Emirates, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Today the President of Elite Petro & Gas, Mr. George Matharu and the President of Tabarak Investment Capital Limited (Investment Bank), Dr. Mohamed Ahmadi announced a deal in which the two companies will use their combined resources to execute physical commodity trades, and provide banking and finance facilities for oil and gas transactions. The alliance between the two entities will also allow compliance related activities to be carried out from two major international hubs of London and Dubai. This increases the international presence of both companies. Additionally, Elite Petro & Gas (“EPG”) has recently formed relationships with the owners of a number of high profile European, South American and Chinese projects, which EPG and Tabarak can work on together. Tabarak Investment Capital Limited is a regulated investment bank by Dubai Financial Services Authority and incorporated in the Dubai International Financial Centre.

MASH ANNOUNCES EUR 50M EQUITY ROUND AND LAUNCH OF EUROPE'S FIRST STO17.10.2018 15:14Pressemelding

Mash Group, a ten year old digital lender and pay later solution provider, announced a EUR 50M equity round and the launch of a Security Token Offering (STO) Helsinki, 17th October: Mash Group Plc, a Finnish FinTech company specializing in consumer lending and pay later solutions, today announced that pre-registration has begun for a Securitized Token Offering (STO). Mash is partnering with DLA Piper, Trust and Tokeny to offer professional investors the means to participate in the current equity round using both crypto and fiat currency. Deloitte has been selected to provide AML and KYC services. The whitelisting process will begin in October with the round closing in December 2018. The STO is part of Mash’s broader EUR 50 million equity round. Security tokens are not the same as utility tokens, as have been issued in a number of recent initial coin offerings (ICOs). The Mash security tokens are backed by assets and token holders would have voting rights and dividend rights of the comp

Meizu officially launches its Overseas smartphone17.10.2018 15:13Pressemelding

Jakarta, Indonesia, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Meizu officially launches its Overseas smartphone, produced in and to be sold in the Indonesian market, the C9, as well as 4 other fantastic products, including the Flagship Meizu 16th, the upgraded M6T, POP true wireless earphones and EP52 Lite. A photo accompanying this announcement is available at https://i.imgur.com/C4LvxTd.png ( Jakarta, Indonesia October 15th, 2018) -- Meizu is releasing 5 exciting products, including 3 smartphone models, its iconic flagship 16th, M6T, C9, POP and EP52 Lite earphones). Meizu’s product launch event is set for the 15th October 2018 at the Pullman hotel in Jakarta Indonesia, with a great line-up of speakers, including Meizu’s Co-Founder and Overseas President Mr Guo, and overseas Head of Marketing and packed with over 150 of Indonesia’s top media, bloggers and fans, it’s set to be a fantastic event all round. Meizu is releasing five great products and introducing 2 years’ warranty on their smartp

eVestment Launches Market Lens to Arm Asset Managers with Next Level Insights to Win More Institutional Investment Mandates17.10.2018 15:00Pressemelding

ATLANTA, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Institutional asset managers looking for the next level of insights in their pursuit of institutional investment mandates can now turn to Market Lens from eVestment, a global leader in institutional investor data and analytics. Market Lens offers a robust feature set including a comprehensive mandate database; investor, consultant and manager profiles; and more than 35,000 documents, audio recordings and videos. These assets include manager presentations, consultant recommendations and research. The new solution also features customized email alerts, saved searches and export capabilities for easy integration into client workflows. The underlying public fund documents allow Market Lens to feature unique investment insights, including product ratings, target asset allocation, actual negotiated fees paid and, leveraging eVestment relationships with institutional investment consultants, undisclosed consultant search data. “In their efforts to win

Kofax Intelligent Automation Deployment at Davies Turner Wins Ventana Award for Overall Digital Leadership17.10.2018 12:00Pressemelding

Project Recognized for Driving Real-Time Insight into Shipments and Inventory to Transform the Customer Experience; Other Kofax Customers also Receive Accolades IRVINE, Calif., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Kofax ® , a leading supplier of intelligent automation (IA) software to digitally transform end-to-end business processes, today announced its customer Davies Turner, one of the UK’s leading multimodal freight forwarding and logistics companies, won the 2018 Overall Digital Leadership Award from Ventana Research for its successful implementation of Kofax Intelligent Automation. Kofax customers Pinnacol Assurance and PITT-OHIO were also recognized. “Davies Turner’s commitment to automation was ambitious but the perfect match for Kofax Intelligent Automation,” said Reynolds C. Bish, Chief Executive Officer of Kofax. “This award is a great illustration of how Kofax enables increased productivity to help organizations remain on track for profitable growth and significant competitive

2018 European Cost Insight Product Cost Management Conference17.10.2018 10:00Pressemelding

Companies from Across Europe to Gather and Discuss How PCM Strategies & Technologies Improve Profitability & Accelerate Design to Delivery Time CONCORD, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- aPriori, the leading provider of enterprise product cost management (PCM) software solutions, announces today that it will host the European Cost Insight Product Cost Management Conference on November 26-28, 2018. This year’s event is being held at Hilton Amsterdam Airport Schiphol in Amsterdam, The Netherlands. This event is open to both aPriori customers and representatives from any manufacturers that are interested in learning more about product cost management technology and best practices. Visit the Cost Insight 2018 Event Website for complete information and register for this year’s program. Why Should You Attend Cost Insight 2018? As pressure increases to deliver innovative and customized products to market faster, manufacturers are struggling to maintain product profits and accelerate de

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom